SG11202109441UA - Methods of anti-tumor therapy - Google Patents

Methods of anti-tumor therapy

Info

Publication number
SG11202109441UA
SG11202109441UA SG11202109441UA SG11202109441UA SG11202109441UA SG 11202109441U A SG11202109441U A SG 11202109441UA SG 11202109441U A SG11202109441U A SG 11202109441UA SG 11202109441U A SG11202109441U A SG 11202109441UA SG 11202109441U A SG11202109441U A SG 11202109441UA
Authority
SG
Singapore
Prior art keywords
methods
tumor therapy
tumor
therapy
Prior art date
Application number
SG11202109441UA
Inventor
Minei Tamar Rachmilewitz
Itzhak Mendel
Niva Yacov
Eyal Breitbart
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of SG11202109441UA publication Critical patent/SG11202109441UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202109441UA 2019-04-12 2020-04-13 Methods of anti-tumor therapy SG11202109441UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833402P 2019-04-12 2019-04-12
PCT/IB2020/053477 WO2020208612A1 (en) 2019-04-12 2020-04-13 Methods of anti-tumor therapy

Publications (1)

Publication Number Publication Date
SG11202109441UA true SG11202109441UA (en) 2021-09-29

Family

ID=70333996

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109441UA SG11202109441UA (en) 2019-04-12 2020-04-13 Methods of anti-tumor therapy

Country Status (13)

Country Link
US (1) US20220185891A1 (en)
EP (1) EP3952903A1 (en)
JP (1) JP2022528425A (en)
KR (1) KR20210152504A (en)
CN (1) CN113710265A (en)
AU (1) AU2020271998A1 (en)
BR (1) BR112021020225A2 (en)
CA (1) CA3134080A1 (en)
EA (1) EA202192800A1 (en)
IL (1) IL287135A (en)
MX (1) MX2021012398A (en)
SG (1) SG11202109441UA (en)
WO (1) WO2020208612A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245249A1 (en) * 2022-06-22 2023-12-28 Race Oncology Ltd Treatment of melanoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
RS60033B1 (en) 2009-11-24 2020-04-30 Medimmune Ltd Targeted binding agents against b7-h1
JP6196040B2 (en) 2010-01-05 2017-09-13 バスキュラー バイオジェニックス リミテッド Usage of specific anti-angiogenic adenoviral agents
SG10201500048SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
CN103261298B (en) 2010-10-18 2014-07-16 道达尔研究技术弗吕公司 Expandable vinyl aromatic polymers
BR112014012819B1 (en) 2011-11-28 2022-08-16 Merck Patent Gmbh ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
SG11201502941VA (en) * 2012-10-17 2015-05-28 Vascular Biogenics Ltd Treatment methods using adenovirus
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
EP3161003A2 (en) * 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors

Also Published As

Publication number Publication date
CN113710265A (en) 2021-11-26
AU2020271998A1 (en) 2021-09-30
JP2022528425A (en) 2022-06-10
US20220185891A1 (en) 2022-06-16
BR112021020225A2 (en) 2021-12-07
IL287135A (en) 2021-12-01
EA202192800A1 (en) 2022-03-30
EP3952903A1 (en) 2022-02-16
KR20210152504A (en) 2021-12-15
CA3134080A1 (en) 2020-10-15
MX2021012398A (en) 2021-11-12
WO2020208612A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
EP3883580A4 (en) Methods of treating cancers
EP3937964A4 (en) Treatment of oncogene-driven cancers
ZA202206743B (en) Therapy for the treatment of cancer
SG11202011117VA (en) Treatment of cancer
SG11202010793UA (en) Methods of treating cancer
IL292502A (en) Therapeutic methods using vadadustat
IL279591A (en) Methods of treating cancer using combination therapy
IL292657A (en) Therapeutic derivatives of interleukin-22
GB201900702D0 (en) Therapy
EP3573701A4 (en) Adjustment of therapeutic stimulation
SG11202107017TA (en) Methods of treating cancer
EP3787693A4 (en) Methods of gene therapy
GB201800736D0 (en) Combination therapy for treatment of leukemia
IL281600A (en) Methods of treating cancer
GB202020573D0 (en) Novel methods of therapy
IL277981A (en) Methods of treating cancer
IL287135A (en) Methods of anti-tumor therapy
IL286353A (en) Combinations of iadademstat for cancer therapy
GB202020572D0 (en) Novel methods of therapy
IL286198A (en) Methods of anti-tumor therapy
IL263905A (en) Combination therapy of cancer
GB201812861D0 (en) Methods of administering therapy
GB201821207D0 (en) Immunotherapy therapy
IL290983A (en) Methods of treatment
GB201918853D0 (en) Methods of treatment